Trial Profile
An Open Label, Randomized, Single Dose, Cross Over Study to Evaluate Food Effects on Relative Bioavailability of RP6530 Administered in Fasting and Fed Conditions in Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Nov 2017
Price :
$35
*
At a glance
- Drugs Tenalisib (Primary)
- Indications Haematological malignancies; Multiple myeloma
- Focus Pharmacokinetics
- Sponsors Rhizen Pharmaceuticals
- 04 Apr 2016 Status changed from recruiting to completed, according to ClinicalTrials.gov record.
- 26 Feb 2016 New trial record